ufk4dzup

Property	Value
?:abstract	BACKGROUND: This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively recorded all the COVID-19 ILI events. PATIENTS AND METHODS: Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared the national emergency. The prevalence of confirmed COVID-19 cases was detected as ILI episode with laboratory confirmation of SARS-CoV-2. Cases with clinical-radiological diagnosis of COVID-19 (COVID-like ILIs), were also reported. RESULTS: Out of 1257 enrolled patients, 955 matched the inclusion criteria for this unplanned analysis. From 31 January to 30 April 2020, 66 patients had ILI: 9 of 955 cases were confirmed COVID-19 ILIs, with prevalence of 0.9% [95% confidence interval (CI): 0.3–2.4], a hospitalization rate of 100% and a mortality rate of 77.8%. Including 5 COVID-like ILIs, the overall COVID-19 prevalence was 1.5% (95% CI: 0.5–3.1), with 100% hospitalization and 64% mortality. The presence of elderly, males and comorbidities was significantly higher among patients vaccinated against influenza versus unvaccinated (p = 0.009, p < 0.0001, p < 0.0001). Overall COVID-19 prevalence was 1.2% for vaccinated (six of 482 cases, all confirmed) and 1.7% for unvaccinated (8 of 473, 3 confirmed COVID-19 and 5 COVID-like), p = 0.52. The difference remained non-significant, considering confirmed COVID-19 only (p = 0.33). CONCLUSION: COVID-19 has a meaningful clinical impact on the cancer-patient population receiving ICIs, with high prevalence, hospitalization and an alarming mortality rate among symptomatic cases. Influenza vaccination does not protect from SARS-CoV-2 infection.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/ufk4dzup_hasAnnotation_C0009566> <https://research.tib.eu/covid-19/entity/ufk4dzup_hasAnnotation_C0392171> <https://research.tib.eu/covid-19/entity/ufk4dzup_hasAnnotation_C0877373> <https://research.tib.eu/covid-19/entity/ufk4dzup_hasAnnotation_C1825598> <https://research.tib.eu/covid-19/entity/ufk4dzup_hasAnnotation_C3541329> <https://research.tib.eu/covid-19/entity/ufk4dzup_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Bersanelli%2C_Melissa%3B_Giannarelli%2C_Diana%3B_De_Giorgi%2C_Ugo%3B_Pignata%2C_Sandro%3B_Di_Maio%2C_Massimo%3B_Verzoni%2C_Elena%3B_Clemente%2C_Alberto%3B_Guadalupi%2C_Valentina%3B_Signorelli%2C_Diego%3B_Tiseo%2C_Marcello%3B_Giusti%2C_Raffaele%3B_Filetti%2C_Marco%3B_Di_Napoli%2C_Marilena%3B_Calvetti%2C_Lorenzo%3B_Cappetta%2C_Alessandro%3B_Ermacora%2C_Paola%3B_Zara%2C_Diego%3B_Barbieri%2C_Fausto%3B_Baldessari%2C_Cinzia%3B_Scotti%2C_Vieri%3B_Mazzoni%2C_Francesca%3B_Veccia%2C_Antonello%3B_Guglielmini%2C_Pamela_Francesca%3B_Maruzzo%2C_Marco%3B_Rossi%2C_Ernesto%3B_Grossi%2C_Francesco%3B_Casadei%2C_Chiara%3B_Cortellini%2C_Alessio%3B_Verderame%2C_Francesco%3B_Montesarchio%2C_Vincenzo%3B_Rizzo%2C_Mimma%3B_Mencoboni%2C_Manlio%3B_Zustovich%2C_Fable%3B_Fratino%2C_Lucia%3B_Cinieri%2C_Saverio%3B_Negrini%2C_Giorgia%3B_Banzi%2C_Maria%3B_Sorar%C3%B9%2C_Mariella%3B_Zucali%2C_Paolo_Andrea%3B_Lacidogna%2C_Gaetano%3B_Russo%2C_Antonio%3B_Battelli%2C_Nicola%3B_Fornarini%2C_Giuseppe%3B_Mucciarini%2C_Claudia%3B_Bracarda%2C_Sergio%3B_Bonetti%2C_Andrea%3B_Pezzuolo%2C_Debora%3B_Longo%2C_Lucia%3B_Sartori%2C_Donata%3B_Iannopollo%2C_Mauro%3B_Cavanna%2C_Luigi%3B_Meriggi%2C_Fausto%3B_Tassinari%2C_Davide%3B_Corbo%2C_Claudia%3B_Gernone%2C_Angela%3B_Prati%2C_Veronica%3B_Carnio%2C_Simona%3B_Giordano%2C_Pasqualina%3B_Dicorato%2C_Angela_Maria%3B_Verusio%2C_Claudio%3B_Atzori%2C_Francesco%3B_Carrozza%2C_Francesco%3B_Gori%2C_Stefania%3B_Castro%2C_Antonino%3B_Pilotto%2C_Sara%3B_Vaccaro%2C_Vanja%3B_Garzoli%2C_Elisabetta%3B_Di_Costanzo%2C_Francesco%3B_Maiello%2C_Evaristo%3B_Labianca%2C_Roberto%3B_Pinto%2C_Carmine%3B_Tognetto%2C_Michele%3B_Buti%2C_Sebastiano>
?:doi	<https://research.tib.eu/covid-19/entity/10.1177/1758835920968463>
?:doi	10.1177/1758835920968463
?:journal	Ther_Adv_Med_Oncol
?:license	cc-by-nc
?:pdf_json_files	document_parses/pdf_json/70273f2f519b7dfbdb6f2e83a3dad8a859c06696.json; document_parses/pdf_json/c82a3048561310b06070dad224b1de0e1c7fb4b0.json
?:pmc_json_files	document_parses/pmc_json/PMC7649863.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7649863>
?:pmid	<https://research.tib.eu/covid-19/entity/33224275.0>
?:pmid	33224275.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:sha_id	<https://research.tib.eu/covid-19/entity/70273f2f519b7dfbdb6f2e83a3dad8a859c06696%3B%20c82a3048561310b06070dad224b1de0e1c7fb4b0>
?:source	Medline; PMC
?:title	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-11-02

Property

Value

?:abstract

BACKGROUND: This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively recorded all the COVID-19 ILI events. PATIENTS AND METHODS: Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared the national emergency. The prevalence of confirmed COVID-19 cases was detected as ILI episode with laboratory confirmation of SARS-CoV-2. Cases with clinical-radiological diagnosis of COVID-19 (COVID-like ILIs), were also reported. RESULTS: Out of 1257 enrolled patients, 955 matched the inclusion criteria for this unplanned analysis. From 31 January to 30 April 2020, 66 patients had ILI: 9 of 955 cases were confirmed COVID-19 ILIs, with prevalence of 0.9% [95% confidence interval (CI): 0.3–2.4], a hospitalization rate of 100% and a mortality rate of 77.8%. Including 5 COVID-like ILIs, the overall COVID-19 prevalence was 1.5% (95% CI: 0.5–3.1), with 100% hospitalization and 64% mortality. The presence of elderly, males and comorbidities was significantly higher among patients vaccinated against influenza versus unvaccinated (p = 0.009, p < 0.0001, p < 0.0001). Overall COVID-19 prevalence was 1.2% for vaccinated (six of 482 cases, all confirmed) and 1.7% for unvaccinated (8 of 473, 3 confirmed COVID-19 and 5 COVID-like), p = 0.52. The difference remained non-significant, considering confirmed COVID-19 only (p = 0.33). CONCLUSION: COVID-19 has a meaningful clinical impact on the cancer-patient population receiving ICIs, with high prevalence, hospitalization and an alarming mortality rate among symptomatic cases. Influenza vaccination does not protect from SARS-CoV-2 infection.

is ?:annotates of

?:creator

<https://research.tib.eu/covid-19/entity/Bersanelli%2C_Melissa%3B_Giannarelli%2C_Diana%3B_De_Giorgi%2C_Ugo%3B_Pignata%2C_Sandro%3B_Di_Maio%2C_Massimo%3B_Verzoni%2C_Elena%3B_Clemente%2C_Alberto%3B_Guadalupi%2C_Valentina%3B_Signorelli%2C_Diego%3B_Tiseo%2C_Marcello%3B_Giusti%2C_Raffaele%3B_Filetti%2C_Marco%3B_Di_Napoli%2C_Marilena%3B_Calvetti%2C_Lorenzo%3B_Cappetta%2C_Alessandro%3B_Ermacora%2C_Paola%3B_Zara%2C_Diego%3B_Barbieri%2C_Fausto%3B_Baldessari%2C_Cinzia%3B_Scotti%2C_Vieri%3B_Mazzoni%2C_Francesca%3B_Veccia%2C_Antonello%3B_Guglielmini%2C_Pamela_Francesca%3B_Maruzzo%2C_Marco%3B_Rossi%2C_Ernesto%3B_Grossi%2C_Francesco%3B_Casadei%2C_Chiara%3B_Cortellini%2C_Alessio%3B_Verderame%2C_Francesco%3B_Montesarchio%2C_Vincenzo%3B_Rizzo%2C_Mimma%3B_Mencoboni%2C_Manlio%3B_Zustovich%2C_Fable%3B_Fratino%2C_Lucia%3B_Cinieri%2C_Saverio%3B_Negrini%2C_Giorgia%3B_Banzi%2C_Maria%3B_Sorar%C3%B9%2C_Mariella%3B_Zucali%2C_Paolo_Andrea%3B_Lacidogna%2C_Gaetano%3B_Russo%2C_Antonio%3B_Battelli%2C_Nicola%3B_Fornarini%2C_Giuseppe%3B_Mucciarini%2C_Claudia%3B_Bracarda%2C_Sergio%3B_Bonetti%2C_Andrea%3B_Pezzuolo%2C_Debora%3B_Longo%2C_Lucia%3B_Sartori%2C_Donata%3B_Iannopollo%2C_Mauro%3B_Cavanna%2C_Luigi%3B_Meriggi%2C_Fausto%3B_Tassinari%2C_Davide%3B_Corbo%2C_Claudia%3B_Gernone%2C_Angela%3B_Prati%2C_Veronica%3B_Carnio%2C_Simona%3B_Giordano%2C_Pasqualina%3B_Dicorato%2C_Angela_Maria%3B_Verusio%2C_Claudio%3B_Atzori%2C_Francesco%3B_Carrozza%2C_Francesco%3B_Gori%2C_Stefania%3B_Castro%2C_Antonino%3B_Pilotto%2C_Sara%3B_Vaccaro%2C_Vanja%3B_Garzoli%2C_Elisabetta%3B_Di_Costanzo%2C_Francesco%3B_Maiello%2C_Evaristo%3B_Labianca%2C_Roberto%3B_Pinto%2C_Carmine%3B_Tognetto%2C_Michele%3B_Buti%2C_Sebastiano>

?:doi

<https://research.tib.eu/covid-19/entity/10.1177/1758835920968463>

?:doi

10.1177/1758835920968463

?:journal

Ther_Adv_Med_Oncol

?:license

cc-by-nc

?:pdf_json_files

document_parses/pdf_json/70273f2f519b7dfbdb6f2e83a3dad8a859c06696.json; document_parses/pdf_json/c82a3048561310b06070dad224b1de0e1c7fb4b0.json

?:pmc_json_files

document_parses/pmc_json/PMC7649863.xml.json

?:pmcid

<https://research.tib.eu/covid-19/entity/PMC7649863>

?:pmid

<https://research.tib.eu/covid-19/entity/33224275.0>

?:pmid

33224275.0

?:publication_isRelatedTo_Disease

<https://research.tib.eu/covid-19/entity/COVID-19>

?:sha_id

<https://research.tib.eu/covid-19/entity/70273f2f519b7dfbdb6f2e83a3dad8a859c06696%3B%20c82a3048561310b06070dad224b1de0e1c7fb4b0>

?:source

Medline; PMC

?:title

Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG

?:type

<https://research.tib.eu/covid-19/vocab/Publication>

?:year

2020-11-02

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/ufk4dzup>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/ufk4dzup>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

Metadata